Why did Sharfstein bolt from the FDA?; TetraLogic closes on $23M tranche; Argen-X to partner with Lilly on antibodies

@FierceBiotech: Pfizer ups ante on Santaris RNA discovery deal with $614M pact. News | Follow @FierceBiotech

@JohnCFierce: Gotta love Novartis' new Wheresflu app to support its cold meds; hypochondriacs will LOVE it. Report | Follow @JohnCFierce

> Joshua Sharfstein's sudden departure from the FDA has triggered some intense speculation about what caused his decision to take the job of Maryland's Secretary of Health. InVivo sees it as a critical repositioning as the agency faces a resurgent Republican Party on Capitol Hill. Story

> Cancer drug developer TetraLogic Pharmaceuticals has closed the $23 million second tranche of a Series C financing completed in October 2010. TetraLogic release

> ArGEN-X BV has forged an alliance with Eli Lilly to discover and develop novel therapeutic antibody products against targets submitted by Lilly. arGen-X Release

> EyeGate Pharma, which is developing ocular therapeutics, has secured an additional $5.9 million as part of its Series D closing. With this additional tranche, Eyegate has raised a total of $28.5M in Series D funding to date. EyeGate release

> AstraZeneca has struck a deal to deploy Kinaxo's high-end mass spectrometry-based technologies to quantitatively analyze posttranslational protein modifications on a proteome-wide scale. Kinaxo release

And Finally... New insights on the AMPK-SRC-2 pathway-a "critical tuning dial for controlling whole body energy"--could help pave the way to new therapies for obesity. Release